Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children with Hematoplastic Disease

Wei Zhao

Status and phase

Enrolling

Phase 4

Conditions

Hematological Neoplasms

Treatments

Drug: Imatinib

Drug: Eltrombopag

Drug: Anti-Infective Drugs

Drug: PEGylated Recombinant Human Granulocyte Colony-Stimulating Factor

Drug: Bortezomib

Drug: Pegaspargase

Drug: dasatinib

Study type

Interventional

Funder types

Other

Identifiers

NCT03844360

Antineoplastic Drugs001

Details and patient eligibility

About

The investigators' purpose was to assess the feasibility of dosage individualization of the commonly used antineoplastic drugs and anti-infective drugs in children with hematoplastic disease.

Full description

The investigators' purpose was to assess the feasibility of dosage individualization of the commonly used antineoplastic drugs and anti-infective drugs based on the opportunistic sampling strategy in children with confirmed or suspected hematological neoplasms.

Enrollment

1,500 estimated patients

Sex

All

Ages

1 day to 18 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients must be diagnosed with hematological neoplasms
Antineoplastic drugs or anti-infective drugs used as part of regular treatment

Exclusion criteria

expected survival time less than the treatment cycle;
patients with other factors that researcher considers unsuitable for inclusion.

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

1,500 participants in 1 patient group

Antineoplastic Drugs and Anti-infective Drugs

Experimental group

Description:

Bortezomib;eltrombopag;imatinib;dasatinib, pegaspargase and anti-infective drugs administered at standard dose for children with hematological neoplasms.